US Patent

US11389461 — Spironolactone aqueous compositions

Formulation · Assigned to CMP Development LLC · Expires 2036-10-28 · 10y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable, ready-to-use liquid formulation of spironolactone, which is also known as Aldactone.

USPTO Abstract

Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.

Drugs covered by this patent

Aldactone (spironolactone) · Generic (originally Searle/Pfizer)

Patent Metadata

Patent number: US11389461
Jurisdiction: US
Classification: Formulation
Expires: 2036-10-28
Drug substance claim: No
Drug product claim: Yes
Assignee: CMP Development LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.